1
|
Nicolas J, Cao D, Claessen B, Sartori S, Roumeliotis A, Goel R, Chandiramani R, Stefanini G, Turfah A, Chen S, Dangas G, Baber U, Sharma S, Kini A, Mehran R. Intersection of the Academic Research Consortium – high bleeding risk criteria in patients undergoing PCI for acute coronary syndromes: insights from a high-volume single centre registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Patients presenting for percutaneous coronary intervention (PCI) with acute coronary syndromes (ACS) often have overlapping bleeding and ischaemic risk factors that offset the long-term success of PCI and limit the post stenting therapeutic options. Aiming at improving outcomes following PCI, the Academic Research Consortium (ARC) recently published a set of major and minor criteria that identify, a priori, patients at high bleeding risk (HBR). Indeed, knowledge of these risk factors will help in optimization of pre-procedural therapy and minimization of post intervention complications. Nonetheless, the actual prevalence of these criteria among patients undergoing PCI for ACS is not well known.
Purpose
To determine the intersection and distribution of ARC-HBR major and minor criteria in a real-world ACS population presenting for PCI.
Methods
In this analysis, we included all patients who presented with ACS to a high-volume PCI centre from 2012 to 2017 and underwent PCI with 2nd generation drug-eluting stent (DES) implantation. Patients were then classified as HBR if they met ≥1 major or ≥2 minor criteria according to the ARC-HBR definition. Baseline clinical and procedural characteristics were extracted from each patient electronic health records. The most common exclusive intersections of ARC-HBR major and minor criteria were quantitatively visualized using an Upset Plot.
Results
Only 44.6% (n=2,717) of ACS patients (n=6,097) fulfilled the ARC-HBR definition. There were significant differences in baseline clinical characteristics between HBR and non-HBR groups: age (71.4±11.5 vs. 60.9±10.3 years, p<0.001), females (40.7% vs. 25.5%, p<0.001), cerebrovascular disease (19.5% vs. 3.9%, p<0.001), and diabetes (55.4% vs. 42.1%, p<0.001). The prevalence of active smoking, a major risk factor for bleeding, was higher in the non-HBR group (20.6% vs. 9.9%, p<0.001). The most frequent major and minor criteria were severe anemia (n=1,072) and age ≥75 (n=1,264), respectively. The top five criteria intersections were: severe anemia (n=215), age ≥75 and moderate chronic kidney disease (CKD) (n=145); moderate CKD and mild anemia (n=142); age ≥75 and mild anemia (n=140); age ≥75, moderate CKD, and mild anemia (n=130) (Figure 1).
Conclusion
Among patients who have undergone PCI for ACS, a significant proportion of individuals fulfilled the ARC-HBR definition. Severe anemia was the most prevalent major criteria. Different combinations of minor criteria, mainly age ≥75, moderate CKD and mild anemia, represented the most common intersections.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- J Nicolas
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - D Cao
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - B Claessen
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - S Sartori
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Roumeliotis
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Goel
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Chandiramani
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - G Stefanini
- UOS of Milan and Humanitas Clinical and Research Center, Cardiology, Milan, Italy
| | - A Turfah
- UOS of Milan and Humanitas Clinical and Research Center, Cardiology, Milan, Italy
| | - S Chen
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - G Dangas
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - U Baber
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - S Sharma
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Kini
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Mehran
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| |
Collapse
|
2
|
Chandiramani R, Cao D, Claessen B, Sartori S, Nicolas J, Roumeliotis A, Goel R, Chiarito M, Power D, Camaj A, Dangas G, Baber U, Sharma S, Kini A, Mehran R. Are the minor high bleeding risk criteria of the academic research consortium truly minor? Insights from a high-volume tertiary care pci centre. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The Academic Research Consortium (ARC) has recently published a consensus-based definition to identify patients at high bleeding risk (HBR), reflected by a BARC 3 or 5 bleeding rate of ≥4% at 1 year after percutaneous coronary intervention (PCI). The HBR criteria included in the definition are divided into minor and major categories, with patients deemed to be at HBR if they fulfill at least one major or two minor criteria. As a result, patients who present with only one minor criterion are categorized as non-HBR.
Purpose
To compare the differences in baseline characteristics and 1-year bleeding and ischaemic outcomes between non-HBR patients undergoing PCI that present with only one minor HBR criterion versus those that do not fulfill any HBR criteria.
Methods
The study population consisted of all consecutive patients who underwent PCI with stent implantation in a single high-volume centre from January 2014 to December 2017. Patients were classified as non-HBR if they did not fulfill at least one major or two minor ARC-HBR criteria. The outcomes of interest were major bleeding (composite of peri-procedural and post-discharge bleeding), all-cause death, and myocardial infarction (MI) at 1 year. The Kaplan-Meier method was used for time-to-event analyses, with comparative risks being assessed using Cox regression.
Results
Of the 9,623 patients included in the analysis, 5,345 were classified as non-HBR. Within the non-HBR patients, 2,078 (38.9%) presented with only one minor HBR criterion and 3,267 (61.1%) presented with no HBR criteria. Non-HBR patients with one minor criterion were more often female, significantly older, with a higher burden of comorbidities such as diabetes mellitus, hypertension and hyperlipidaemia, and more likely to have multivessel disease as well as a history of prior MI and revascularisation, while non-HBR patients with no criteria were more likely to be smokers and have a higher BMI. Distribution of the minor HBR criteria within the group presenting with one minor criterion are illustrated in the figure. Non-HBR patients with only one minor criterion had a numerically higher rate of major bleeding compared to non-HBR patients with no criteria (3.6% vs. 2.9%, p=0.09). While the rate of all-cause death was significantly higher in the group with only one minor criterion (1.2% vs. 0.4%, p=0.004), there was no difference in the rate of MI between the two groups (2.1% vs. 1.9%, p=0.83). Hazard ratios comparing the two groups are presented in the figure.
Conclusions
Non-HBR patients presenting with only one minor criterion had a numerically higher rate of post-PCI bleeding and significantly higher mortality compared to those without any criteria. Nonetheless, the major bleeding rates of both groups at 1 year were less than the 4% cutoff to qualify as HBR according to the ARC definition, thereby supporting their inclusion as “minor” criteria in the recent ARC-HBR definition.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- R Chandiramani
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - D Cao
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - B Claessen
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - S Sartori
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - J Nicolas
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Roumeliotis
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Goel
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - M Chiarito
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - D Power
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Camaj
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - G Dangas
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - U Baber
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - S Sharma
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Kini
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Mehran
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| |
Collapse
|
3
|
Roumeliotis A, Mehran R, Claessen B, Sartori S, Cao D, Chandiramani R, Nicolas J, Goel R, Reisman A, Baber U, Sweeny J, Barman N, Dangas G, Sharma S, Kini A. Impact of high-density lipoprotein levels in males and females undergoing percutaneous coronary intervention with drug eluting stents. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Introduction
Low levels of high-density lipoprotein (HDL) have been associated with adverse cardiovascular events in multiple epidemiological studies. Evidence regarding the role of HDL in males and females with established coronary artery disease undergoing percutaneous coronary intervention (PCI) with drug eluting stents (DES) is scarce.
Purpose
We sought to investigate the impact of low HDL levels on 1-year cardiovascular outcomes in males and females undergoing PCI with DES.
Methods
We screened all patients undergoing PCI in our center from 2012 to 2017. Exclusion criteria were: unavailable baseline HDL measurement, age <18 years, presentation with ST-segment elevation myocardial infarction (MI) or shock, coexisting neoplastic disease and treatment without a stent or with a bare metal stent. The final population was divided by gender and further stratified to the high or low HDL group according to baseline HDL levels. Cut-offs were 40mg/dL in males and 50mg/dL in females, per the most recent ACC/AHA guideline recommendations. The primary endpoint of the analysis was major adverse cardiovascular events (MACE) at 1 year, defined as death, MI or target vessel revascularization (TVR). To account for potential clinical and anatomical confounders the outcomes were also adjusted for age, Caucasian ethnicity, hypertension, diabetes mellitus (DM), body mass index, smoking, prior MI, multi-vessel disease and type B2/C lesions.
Results
Out of the 10,843 patients included, 7,718 (71.2%) were male and 3,125 (28.8%) were female. Low HDL was noted in 58.5% of males and 63.8% of females. Patients with low HDL were younger and had a higher prevalence of DM, prior MI, smoking and multi-vessel disease. When comparing low to high HDL groups in terms of 1-year MACE a borderline significant difference was shown in males (7.4% vs. 6.0%; p-value=0.08) but not in females (7.7% vs 8.1%; p-value=0.90) [Panel A]. The numerically higher incidence of MACE in males with low HDL was primarily driven by TVR (5.4% vs 3.7%; p-value=0.005) while the rates of Death (1.4% vs. 1.3%; p=0.96) and MI (2.0% vs. 1.8%; p-value=0.89) were similar between the two groups. After adjustment the male low HDL subgroup remained at a higher risk for 1-year TVR but not 1-year MACE compared to the male high HDL subgroup [Panel B]. No difference for any individual component of MACE was shown between low and high HDL subgroups in females [Panel C].
Conclusion(s)
High HDL levels were associated with a lower incidence of TVR and borderline reduction of MACE in male but not female patients undergoing PCI with DES. No difference was demonstrated in terms of death or MI between the high and low HDL subgroups at 1-year follow-up.
Impact of HDL levels according to gender
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- A Roumeliotis
- Mount Sinai Hospital, New York, United States of America
| | - R Mehran
- Mount Sinai Hospital, New York, United States of America
| | - B Claessen
- Mount Sinai Hospital, New York, United States of America
| | - S Sartori
- Mount Sinai Hospital, New York, United States of America
| | - D Cao
- Mount Sinai Hospital, New York, United States of America
| | - R Chandiramani
- Mount Sinai Hospital, New York, United States of America
| | - J Nicolas
- Mount Sinai Hospital, New York, United States of America
| | - R Goel
- Mount Sinai Hospital, New York, United States of America
| | - A Reisman
- Mount Sinai Hospital, New York, United States of America
| | - U Baber
- Mount Sinai Hospital, New York, United States of America
| | - J Sweeny
- Mount Sinai Hospital, New York, United States of America
| | - N Barman
- Mount Sinai Hospital, New York, United States of America
| | - G Dangas
- Mount Sinai Hospital, New York, United States of America
| | - S Sharma
- Mount Sinai Hospital, New York, United States of America
| | - A Kini
- Mount Sinai Hospital, New York, United States of America
| |
Collapse
|
4
|
Nicolas J, Cao D, Claessen B, Sartori S, Chandiramani R, Roumeliotis A, Goel R, Camaj A, Beerkens F, Turfah A, Dangas G, Baber U, Sharma S, Kini A, Mehran R. Long-term outcomes in high-bleeding risk patients undergoing PCI for acute coronary syndromes: results from a large single-center pci registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Current clinical guidelines recommend prolonged dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndromes (ACS). However, an extended DAPT duration in high-bleeding risk (HBR) patients amplifies the risk of post procedural complications. Hence, clinicians often face the dilemma of prolonging DAPT duration to prevent recurrent ischaemic events at the expense of increasing the incidence of bleeding in high-risk patients. The actual incidence of ischaemic and bleeding events in this particular population is not well elucidated.
Purpose
To evaluate one-year ischemic and bleeding outcomes following PCI for ACS in a real-world HBR population as defined by the Academic Research Consortium (ARC) consensus document.
Methods
We included all patients who presented with ACS to a high-volume single PCI centre from 2012 to 2017 and underwent PCI with 2nd generation drug-eluting stent implantation. Patients were classified as HBR if they met ≥1 major or ≥2 minor criteria according to the recent ARC-HBR consensus. The outcomes of interest were major adverse cardiovascular events (MACE), a composite of all-cause death, myocardial infarction (MI), and target lesion revascularization (TLR), and major bleeding events, including both peri-procedural and post-discharge bleeding. All outcomes were assessed at 1-year follow-up. The Kaplan-Meier method was used for time-to-event analyses.
Results
Out of 6,097 ACS patients included in this analysis, 2,717 (44.6%) fulfilled the ARC-HBR definition. Compared to non-HBR group, HBR patients were more frequently female, older, more likely to have cardiovascular risk factors (e.g., diabetes, hypertension, and hyperlipidemia) and complex coronary artery disease (e.g., multi-vessel disease, bifurcation lesions, and calcification). The 1-year incidence of MACE was significantly higher in HBR patients (16.3% vs. 8.1%, HR 2.16, 95% CI [1.81–2.59], p<0.001) (Figure 1A). This finding was driven by higher rates of all-cause death and MI (Figure 1B). The 1-year incidence of major bleeding was also significantly higher in HBR patients compared to non-HBR (11.1% vs. 3.1%, HR: 3.92, 95% CI 3.10–4.95; p<0.001).
Conclusions
HBR patients undergoing PCI for ACS are not only subject to bleeding complications but are also at an increased risk for ischemic events and all-cause mortality.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- J Nicolas
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - D Cao
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - B Claessen
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - S Sartori
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Chandiramani
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Roumeliotis
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Goel
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Camaj
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - F Beerkens
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Turfah
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - G Dangas
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - U Baber
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - S Sharma
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - A Kini
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| | - R Mehran
- Icahn School of Medicine at Mount Sinai, New York, United States of America
| |
Collapse
|
5
|
Chiarito M, Cao D, Nicolas J, Roumeliotis A, Power D, Chandiramani R, Goel R, Claessen B, Ferrante G, Stefanini G, Mehran R, Dangas G. Radial versus femoral access for coronary angiography and interventions: a systematic review and meta-analysis of randomized trials. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The presence of any benefits associated with radial or femoral access among patients undergoing coronary angiography and percutaneous coronary interventions (PCI) is still debated.
Purpose
Our aim is to provide a comprehensive quantitative appraisal of the effects of access site on the risks of stroke, myocardial infarction, and major bleeding in patients undergoing coronary angiography with or without PCI.
Methods
In January 2020, we searched PubMed, Embase, and meeting abstracts for randomized trials comparing radial versus femoral access for coronary angiography with or without subsequent PCI. Odds ratios (OR) were used as metric of choice for treatment effects with random-effects models. Co-primary efficacy endpoints were stroke and myocardial infarction. Primary safety endpoint was major bleeding. Secondary endpoints were all cause mortality and vascular complications. Heterogeneity was assessed with the I-squared index. This study is registered with PROSPERO.
Results
We identified 31 trials, including 30,414 patients. Risks of stroke (OR 1.11, 95% CI 0.76–1.64, I2=0%) and myocardial infarction (OR 0.90, 95% CI 0.79–1.03, I2=0%) were comparable between radial and femoral access. Radial access was associated with a reduction for the risk of major bleeding as compared to femoral access (OR 0.53, 95% CI 0.42–0.67, I2=3.3%) with a number needed to treat of 92. Findings were consistent regardless clinical features and procedure performed, with the only exception of an increased benefit of the radial access in patients with chronic coronary syndrome (p forinteraction=0.005). The risk for all-cause mortality (OR 0.73, 95% CI 0.61–0.89, I2=0%) and vascular complication (OR 0.32, 95% CI 0.23–0.44, I2=16.7%) was significantly lower in the radial compared to femoral access group.
Conclusions
In patients undergoing coronary angiography with or without PCI, radial compared to femoral access did not reduce the risk of stroke and myocardial infarction, with no impact on the effect estimates of clinical presentation, age, gender, or subsequent PCI. Whereas, radial access is associated with a significant risk reduction of major bleeding as compared to femoral access. The benefit favoring radial access is of important clinical relevance in view of the relatively low number needed to treat to prevent a major bleeding and the significant impact on mortality.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Chiarito
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - D Cao
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - J Nicolas
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - A Roumeliotis
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - D Power
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - R Chandiramani
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - R Goel
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - B.E Claessen
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - G Ferrante
- Istituto Clinico Humanitas, Milan, Italy
| | | | - R Mehran
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| | - G Dangas
- Icahn School of Medicine at Mount Sinai, New York City, United States of America
| |
Collapse
|
6
|
Guedeney P, Sorrentino S, Giustino G, Chapelle C, Claessen B, Ollier E, Laporte S, Camaj A, Kalkman DN, Vogel B, De Rosa S, Indolfi C, Collet JP, Mehran R, Montalescot G. P5367Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0332] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Alirocumab and evolocumab, two proprotein convertase subtilisin–kexin type 9 inhibitors, have both been associated with improved outcomes in patients with atherosclerotic cardiovascular disease in addition to standard lipid-lowering therapies. However, their comparative safety and efficacy profiles are unknown.
Purpose
To compare the safety and efficacy of alirocumab versus evolocumab.
Methods
We conducted a systematic review and network meta-analysis of placebo-controlled randomized trials available up to November 2018 evaluating the safety and efficacy of alirocumab and evolocumab. We estimated risk ratio and 95% confidence intervals using fixed effect model in a frequentist pairwise and network metanalytic approach. The primary safety endpoints were any adverse events leading to treatment-discontinuation, injection site reaction, systemic allergic reaction, neurocognitive events, ophthalmologic events and new-onset of diabetes mellitus (DM) or worsening of pre-existing DM. The primary efficacy endpoints were all-cause and cardiovascular (CV) death, myocardial infarction (MI) and stroke. This study was registered in PROSPERO (CRD42018090768).
Results
A total of 30 trials, enrolling 59,026 patients were included in this analysis, of whom 13,607 received alirocumab and 17,931 received evolocumab. Mean weighted follow-up time was 2.5 years, with an exposure time of 144,907 patients-years. Eligibility criteria varied significantly across trials evaluating alirocumab and evolocumab. There were no significant differences between alirocumab and evolocumab in terms of safety endpoints, except for injection site reaction with a 27% increased risk of injection site reaction with alirocumab compared to evolocumab (Figure). Compared with evolocumab, alirocumab was associated with a reduction of all-cause death but not CV death. There were no significant differences in MI or stroke between alirocumab and evolocumab.
Conclusion
Alirocumab and evolocumab share a similar safety profile. No significant differences were observed across the efficacy endpoints, except for all-cause death, which may be related to heterogeneity of the studied populations between the two drugs.
Collapse
Affiliation(s)
- P Guedeney
- Hospital Pitie-Salpetriere, Paris, France
| | - S Sorrentino
- Magna Graecia University of Catanzaro, Division of cardiology, Department of Medical and Surgical Science, Catanzaro, Italy
| | - G Giustino
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - C Chapelle
- Unité de Recherche Clinique Innovation et Pharmacologie, Universitary Hospital of Saint Etienne, Saint Etienne, France
| | - B Claessen
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - E Ollier
- Unité de Recherche Clinique Innovation et Pharmacologie, Universitary Hospital of Saint Etienne, Saint Etienne, France
| | - S Laporte
- Unité de Recherche Clinique Innovation et Pharmacologie, Universitary Hospital of Saint Etienne, Saint Etienne, France
| | - A Camaj
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - D N Kalkman
- University of Amsterdam, Department of Clinical and Experimental Cardiology, Amsterdam, Netherlands (The)
| | - B Vogel
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - S De Rosa
- Magna Graecia University of Catanzaro, Division of cardiology, Department of Medical and Surgical Science, Catanzaro, Italy
| | - C Indolfi
- Magna Graecia University of Catanzaro, Division of cardiology, Department of Medical and Surgical Science, Catanzaro, Italy
| | - J P Collet
- Hospital Pitie-Salpetriere, Paris, France
| | - R Mehran
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | | |
Collapse
|
7
|
Guedeney P, Claessen B, Mehran R, Mintz G, Liu M, Sorrentino S, Farhan S, Leon MB, Serruys P, Smits PC, Von Birgelen C, Redfors B, Madhavan MV, Ben-Yehuda O, Stone GW. P1966Impact of coronary artery calcification on long-term outcomes after implantation of first and second-generation drug-eluting stents: a patient-level analysis of 18 randomized trials. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Available data on the long-term impact of coronary artery calcification (CAC) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) are limited.
Purpose
We evaluated the long-term impact of CAC on outcomes after PCI and the respective performance of first- and second-generation DES.
Methods
We pooled patient-level data from 18 randomized trials evaluating DES categorized according to the presence of angiographic core lab-confirmed moderate or severe CAC in any target lesion. Outcome measures of interest were the patient-oriented composite endpoint (POCE; death, myocardial infarction [MI], or any revascularization), the device-oriented composite endpoint of target lesion failure (TLF; cardiac death, target vessel MI or ischemia-driven target lesion revascularization), and definite or probable stent thrombosis (ST). Multivariable Cox proportional regression with study as a random effect was used to assess 5-year outcomes.
Results
A total of 19,833 patients were included. Moderate or severe CAC was present in 6211 (31.3%) patients and associated with increased 5-year risk of the POCE (adjHR 1.12, 95% CI 1.05–1.20, p<0.001), TLF (adjHR 1.21, 95% CI 1.09–1.35, p<0.001), and a trend for greater ST (adjHR 1.24, 95% CI 0.99–1.54, p=0.06). In patients with CAC, second-generation DES were associated with a reduction in the 5-year risk of TLF and ST, and a trend for reduced POCE compared with first-generation DES (Table).
Conclusion
In this large-scale study, target lesion moderate or severe CAC was associated with adverse patient- and device-related outcomes at 5 years, risks that were reduced but not eliminated with second-generation DES.
Acknowledgement/Funding
This investigator-sponsored study was funded by Abbott Vascular.
Collapse
Affiliation(s)
- P Guedeney
- Hospital Pitie-Salpetriere, Paris, France
| | - B Claessen
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - R Mehran
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - G Mintz
- Cardiovascular Research Foundation, Clinical trials center, New York, United States of America
| | - M Liu
- Cardiovascular Research Foundation, Clinical trials center, New York, United States of America
| | - S Sorrentino
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - S Farhan
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - M B Leon
- Cardiovascular Research Foundation, Clinical trials center, New York, United States of America
| | - P Serruys
- Imperial College London, Technology and medicine, London, United Kingdom
| | - P C Smits
- Maasstad Ziekenhuis, Cardiology, Rotterdam, Netherlands (The)
| | - C Von Birgelen
- Medical Spectrum Twente, Cardiology, Enschede, Netherlands (The)
| | - B Redfors
- Cardiovascular Research Foundation, Clinical trials center, New York, United States of America
| | - M V Madhavan
- Cardiovascular Research Foundation, Clinical trials center, New York, United States of America
| | - O Ben-Yehuda
- Cardiovascular Research Foundation, Clinical trials center, New York, United States of America
| | - G W Stone
- Cardiovascular Research Foundation, Clinical trials center, New York, United States of America
| |
Collapse
|
8
|
Chandiramani R, Chen H, Cao D, Claessen B, Blum M, Goel R, Sartori S, Aquino M, Guedeney P, Effron M, Keller S, Baker B, Pocock S, Baber U, Mehran R. P1760Incidence and effects of stroke, MI and bleeding on mortality among patients with ACS undergoing PCI: a comparative analysis from the PROMETHEUS registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Stroke represents a potentially calamitous complication among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) even though its rates are relatively low. Data on the distribution of stroke occurrence over time and its overlap with myocardial infarction (MI) and bleeding after PCI is scarce.
Purpose
We sought to compare the occurrence and impacts of stroke, MI and bleeding on subsequent mortality in ACS patients undergoing PCI in contemporary clinical practice.
Methods
A total of 19,914 ACS patients who underwent PCI in the PROMETHEUS multi-center observational study were analyzed. We calculated the cumulative stroke incidence at 30 days and 1 year using Kaplan Meier (KM) method. We also compared the distribution of stroke, myocardial infarction (MI) and bleeding across time and evaluated the overlap between their occurrences. Predictors of 1 year stroke occurrence were identified through multivariable Cox-regression and stroke, MI and bleeding were entered as time-updated covariates to estimate their individual effects on subsequent mortality.
Results
Of the total number of patients, 244 patients (1.5%) had a stroke within 1 year. 48 of these patients also experienced an MI while another 48 patients experienced a bleeding event. Furthermore, 14 of these overlapping patients experienced a stroke, MI and bleeding event, all within the 1-year follow-up. Patients who sustained a stroke were more likely to have a prior history of cerebrovascular disease, peripheral artery disease, MI and heart failure compared to those who did not have a stroke. Mortality risk was significantly higher among those with stroke versus those without stroke (adjusted HR 4.84, p<0.0001). However, the association attenuated over time with a much larger effect in the first 30 days of its occurrence (adjusted HR 17.7, p<0.0001) versus beyond 30 days (adjusted HR 1.22; 95% CI: 0.6–2.46, p=0.58). Although the effects of MI and bleeding on subsequent mortality within 30 days of occurrence were significantly lower than stroke (adjusted HR 6.22, p<0.0001; adjusted HR 7.30, p<0.0001, respectively), their effects were more sustained on mortality beyond 30 days (adjusted HR 2.89, p<0.0001; adjusted HR 3.05, p<0.0001, respectively).
Conclusion
When compared with MI and bleeding, stroke had a substantially stronger impact on mortality that attenuated rapidly over time among ACS patients undergoing PCI. Optimization of modifiable risk factors and medication adherence are essential parts of management of stroke following PCI for ACS.
Collapse
Affiliation(s)
- R Chandiramani
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - H Chen
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - D Cao
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - B Claessen
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - M Blum
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - R Goel
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - S Sartori
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - M Aquino
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - P Guedeney
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - M Effron
- Eli Lilly and Company, Indianapolis, United States of America
| | - S Keller
- Eli Lilly and Company, Indianapolis, United States of America
| | - B Baker
- Daiichi-Sankyo, Inc, Parsippany, United States of America
| | - S Pocock
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - U Baber
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| | - R Mehran
- The Zena and Michael A. Wiener Cardiovascular Institute, New York, United States of America
| |
Collapse
|
9
|
Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Naber C, Perez-Vizcayno MJ, Baan J, Degenhardt R, Pleva L, Fernandez C, Gao R, Henriques JP, Kastrati A, Byrne R. 1463Differential effectiveness of drug-coated balloon vs. drug-eluting stent for bare-metal or drug-eluting stent restenosis: a primary prespecified subanalysis from the DAEDALUS study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1463] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - F Alfonso
- University Hospital De La Princesa, Madrid, Spain
| | - B Xu
- Fu Wai Hospital, Beijing, China People's Republic of
| | - B Claessen
- Academic Medical Center, Amsterdam, Netherlands
| | | | - C Naber
- Contilia Heart and Vascular Center, Essen, Germany
| | | | - J Baan
- Academic Medical Center, Amsterdam, Netherlands
| | - R Degenhardt
- Heart and Vascular Center, Rotenburg an der Fulda, Germany
| | - L Pleva
- University Hospital Ostrava, Ostrava, Czech Republic
| | | | - R Gao
- Fu Wai Hospital, Beijing, China People's Republic of
| | | | | | - R Byrne
- German Heart Center, Munich, Germany
| |
Collapse
|